ZA201405555B - Fused tricyclic compounds as raf kinase inhibitors - Google Patents
Fused tricyclic compounds as raf kinase inhibitorsInfo
- Publication number
- ZA201405555B ZA201405555B ZA2014/05555A ZA201405555A ZA201405555B ZA 201405555 B ZA201405555 B ZA 201405555B ZA 2014/05555 A ZA2014/05555 A ZA 2014/05555A ZA 201405555 A ZA201405555 A ZA 201405555A ZA 201405555 B ZA201405555 B ZA 201405555B
- Authority
- ZA
- South Africa
- Prior art keywords
- kinase inhibitors
- raf kinase
- tricyclic compounds
- fused tricyclic
- fused
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000009929 raf Kinases Human genes 0.000 title 1
- 108010077182 raf Kinases Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085146 WO2013097224A1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201405555B true ZA201405555B (en) | 2015-10-28 |
Family
ID=48696279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/05555A ZA201405555B (en) | 2011-12-31 | 2014-07-28 | Fused tricyclic compounds as raf kinase inhibitors |
Country Status (28)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401725SA (en) | 2011-12-31 | 2014-09-26 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
| WO2014206344A1 (en) * | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| US9670203B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors |
| WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| KR102643609B1 (ko) * | 2015-04-15 | 2024-03-05 | 베이진 엘티디 | B-raf 키나아제 억제제의 말레에이트 염, 결정질 형태, 제조방법, 및 이의 용도 |
| JP6175519B2 (ja) * | 2016-01-04 | 2017-08-09 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| CN109475536B (zh) * | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| LT3689868T (lt) | 2016-12-01 | 2023-12-27 | Arvinas Operations, Inc. | Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| JP7679173B2 (ja) | 2016-12-23 | 2025-05-19 | アルビナス・オペレーションズ・インコーポレイテッド | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| BR112022003490A2 (pt) | 2019-08-26 | 2022-05-24 | Arvinas Operations Inc | Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida |
| CN118059104A (zh) | 2019-12-19 | 2024-05-24 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| JP2023535790A (ja) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| MX2023002979A (es) | 2020-09-14 | 2023-04-10 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradacion dirigida del receptor de estrogenos. |
| AU2021412688B2 (en) * | 2020-12-29 | 2025-06-12 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| EP4404935A4 (en) * | 2021-09-21 | 2025-07-16 | Merck Sharp & Dohme Llc | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS |
| WO2023212071A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Combination and the use thereof |
| WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| AU2004308299B2 (en) | 2003-12-19 | 2011-11-24 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
| BRPI0610863A2 (pt) | 2005-05-20 | 2010-08-03 | Array Biopharma Inc | compostos inibidores de raf e métodos para sua utilização |
| TWI432193B (zh) | 2005-06-22 | 2014-04-01 | Plexxikon Inc | 用於激酶調節的化合物及方法及其適應症 |
| RU2008112313A (ru) | 2005-09-01 | 2009-10-10 | Эррэй Биофарма Инк. (Us) | Соединения ингибиторы raf и способы их применения |
| ZA200804679B (en) * | 2005-12-08 | 2010-02-24 | Millenium Pharmaceuticals Inc | Bicyclic compounds with kinase inhibitory activity |
| EP2021327B1 (en) * | 2006-05-15 | 2012-04-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| MX2009001913A (es) * | 2006-08-23 | 2009-03-06 | Pfizer Prod Inc | Compuestos de pirimidona como inhibidores de gsk-3. |
| WO2008028617A1 (en) | 2006-09-06 | 2008-03-13 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as protein kinase inhibitors |
| JP2010502706A (ja) * | 2006-09-07 | 2010-01-28 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害活性を有するフェネチルアミド誘導体 |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| CA2686379A1 (en) * | 2007-05-04 | 2008-11-13 | Irm Llc | Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors |
| NZ582772A (en) | 2007-07-17 | 2012-06-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| SG11201401725SA (en) | 2011-12-31 | 2014-09-26 | Beigene Ltd | Fused tricyclic compounds as raf kinase inhibitors |
| KR102643609B1 (ko) | 2015-04-15 | 2024-03-05 | 베이진 엘티디 | B-raf 키나아제 억제제의 말레에이트 염, 결정질 형태, 제조방법, 및 이의 용도 |
-
2011
- 2011-12-31 SG SG11201401725SA patent/SG11201401725SA/en unknown
- 2011-12-31 PT PT118790963T patent/PT2797888T/pt unknown
- 2011-12-31 EP EP16167542.6A patent/EP3124472B1/en active Active
- 2011-12-31 EP EP11879096.3A patent/EP2797888B1/en active Active
- 2011-12-31 MX MX2014007829A patent/MX352617B/es active IP Right Grant
- 2011-12-31 ES ES11879096.3T patent/ES2588775T3/es active Active
- 2011-12-31 KR KR1020147018101A patent/KR101713391B1/ko active Active
- 2011-12-31 NZ NZ624068A patent/NZ624068A/en unknown
- 2011-12-31 EA EA201491305A patent/EA025597B1/ru not_active IP Right Cessation
- 2011-12-31 CN CN201180069798.XA patent/CN103596926B/zh active Active
- 2011-12-31 DK DK11879096.3T patent/DK2797888T3/en active
- 2011-12-31 LT LTEP11879096.3T patent/LT2797888T/lt unknown
- 2011-12-31 US US14/369,379 patent/US9273046B2/en active Active
- 2011-12-31 JP JP2014549294A patent/JP5868521B2/ja active Active
- 2011-12-31 HU HUE11879096A patent/HUE029656T2/en unknown
- 2011-12-31 RS RS20160713A patent/RS55196B1/sr unknown
- 2011-12-31 SI SI201130852A patent/SI2797888T1/sl unknown
- 2011-12-31 PL PL11879096.3T patent/PL2797888T3/pl unknown
- 2011-12-31 IN IN6166DEN2014 patent/IN2014DN06166A/en unknown
- 2011-12-31 AU AU2011384857A patent/AU2011384857B2/en active Active
- 2011-12-31 CA CA2856347A patent/CA2856347C/en active Active
- 2011-12-31 BR BR112014013108-2A patent/BR112014013108B1/pt active IP Right Grant
- 2011-12-31 ME MEP-2016-172A patent/ME02529B/me unknown
- 2011-12-31 HR HRP20160641TT patent/HRP20160641T1/hr unknown
- 2011-12-31 WO PCT/CN2011/085146 patent/WO2013097224A1/en active Application Filing
-
2014
- 2014-06-25 IL IL233364A patent/IL233364A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05555A patent/ZA201405555B/en unknown
-
2016
- 2016-01-22 US US15/004,311 patent/US9895376B2/en active Active
- 2016-09-05 CY CY20161100869T patent/CY1118226T1/el unknown
- 2016-09-06 SM SM201600302T patent/SMT201600302B/it unknown
-
2018
- 2018-01-29 US US15/882,064 patent/US10576087B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289834A (en) | Conversion of tricyclic compounds as fgfr inhibitors | |
| ZA201405555B (en) | Fused tricyclic compounds as raf kinase inhibitors | |
| IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| IL245309B (en) | Heterocyclic tricyclic compounds as jak inhibitors | |
| AP2013007252A0 (en) | Heterocyclic compounds as kinase inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| EP2686317A4 (en) | RAF KINASE INHIBITORS |